Targeting the mechanisms of drug resistance in mantle cell lymphoma
Official title: Mechanism-Based Targeting of Mantle Cell Lymphoma
Funded at Weill Medical Coll of Cornell Univ · NIH-10478980 · Data updated 2026-11-12
This study is looking at why mantle cell lymphoma sometimes stops responding to treatment, and it's for patients who want to help researchers find better ways to fight this cancer by testing a new drug alongside current therapies.
Quick facts
| Grant type | P01 program project |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Weill Medical Coll of Cornell Univ NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project start | September 18, 2018 |
| Project end | August 31, 2025 |
| Funding year | 2022 |
| Award (this year) | $1,737,096 |
| NIH project number | 5P01CA214274-05 |
| Project ID | NIH-10478980 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with mantle cell lymphoma who have experienced treatment resistance.
✕Less likely to help
Patients with other types of lymphoma or those who have not been diagnosed with mantle cell lymphoma may not benefit from this research.
What this research studies
This research focuses on understanding why mantle cell lymphoma (MCL) becomes resistant to treatments, which is a significant challenge in managing this type of cancer. By investigating the genomic and molecular mechanisms behind drug resistance, the researchers aim to develop more effective therapies that can be tailored to individual patients. The approach includes using a drug called palbociclib to halt cancer cell proliferation and enhance the effectiveness of existing treatments like ibrutinib. Patients will be monitored through biopsies to assess their response to these therapies over time.
Why it matters
Potential benefit: If successful, this research could lead to more effective and durable treatment options for patients with mantle cell lymphoma.
How similar studies have gone: Previous research has shown promise in targeting drug resistance in other cancers, suggesting that this approach may also be effective for mantle cell lymphoma.
Where this research is happening
-
Weill Medical Coll of Cornell Univ
New York, United States Active
Researchers
- Principal investigator: Chen-Kiang, Selina Y — Weill Medical Coll of Cornell Univ
- Study coordinator: Chen-Kiang, Selina Y
Related research
Other NIH-funded projects on the same topics.
-
Cyclin D1 and DNA Repair in Mantle Cell Lymphoma: A Path to New Therapies
A clinician-researcher at Mayo Clinic is pursuing advanced training and research to understand how Cyclin D1 drives replication stress and to explore new targeted treatments for high-risk mantle cell lymphoma.
-
Duvelisib for preventing cytokine release syndrome in CAR T-cell therapy patients
A study tests whether taking duvelisib before CAR T-cell therapy can prevent dangerous inflammatory reactions in patients with large B-cell or mantle cell lymphoma.
-
ERBB signaling and ibrutinib resistance in mantle cell lymphoma
A short, patient-friendly look at how scientists study why some mantle cell lymphoma patients stop responding to ibrutinib and how ERBB signaling might be involved.
-
Why some mantle cell lymphomas respond to Notch-blocking drugs
Researchers are looking at DNA regulatory changes to understand why some mantle cell lymphomas respond to drugs that block Notch while others resist them.
-
Preventing a serious side effect of CAR T-cell therapy for lymphoma
This project is testing a new medication called Duvelisib to help prevent a serious immune reaction called cytokine release syndrome in people with large cell or mantle cell lymphoma who are receiving CAR T-cell therapy.
-
Understanding CEACAM1 in Mantle Cell Lymphoma and New Treatments
This research looks for new ways to treat mantle cell lymphoma, especially for patients whose current medications are not working well.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.